Clinical Trials Logo

Nephropathy clinical trials

View clinical trials related to Nephropathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02372695 Terminated - Nephropathy Clinical Trials

Effect of Paricalcitol Over Vessel Wall

MICROBUB
Start date: July 2012
Phase: Phase 4
Study type: Interventional

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

NCT ID: NCT01071993 Terminated - Nephropathy Clinical Trials

Efficacy of Statins In Prevention of CIN

SCIN
Start date: March 2010
Phase: N/A
Study type: Interventional

To determine if statin therapy plus intravenous normal saline, in patients with chronic renal insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline therapy in the prevention of CIN.

NCT ID: NCT00969956 Terminated - Clinical trials for Ischemic Heart Disease

Time To Complications Occurs in Diabetes

Start date: April 2012
Phase:
Study type: Observational

Diabetes causing serious complications is well known. In this study the aim is to follow 950 patients with diabetes for 15 years to study when, in who and how the diabetes complications occurs.

NCT ID: NCT00579995 Terminated - Nephropathy Clinical Trials

A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate

PROTECt
Start date: May 1, 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of oral N-acetylcysteine and intravenous sodium bicarbonate for the prevention of Contrast-Induced Nephropathy (CIN) after cardiac catheterization.

NCT ID: NCT00555217 Terminated - Type 2 Diabetes Clinical Trials

VA NEPHRON-D: Diabetes iN Nephropathy Study

VA NEPHRON-D
Start date: July 2008
Phase: Phase 3
Study type: Interventional

Diabetes is the leading cause of end-stage renal disease (ESRD) in the United States. The overall rate of ESRD secondary to diabetes has risen 68% since 1992. Medications that block the renin angiotensin system have been shown to decrease the progression of diabetic nephropathy. The use of an angiotensin receptor blocker (ARB) has been shown to decrease the risk of progression of kidney disease in two studies of individuals with Type 2 diabetes and proteinuria. Despite the use of an ARB, the incidence of renal failure remained high in the treated group in both studies. The combination of an angiotensin converting enzyme inhibitor (ACEI) and ARB can lead to more complete blockade of the renin angiotensin system. In diabetic kidney disease, combination therapy has been shown to decrease proteinuria in short-term studies. Although there are encouraging results for improvement in proteinuria there are no data on progression of kidney disease for the use of combination of ACEI and ARB therapy in patients with diabetes. In addition, there could be an increased risk of serious hyperkalemia in individuals with diabetes who receive combination ACEI and ARB. The investigators therefore propose a randomized double blind multi-center clinical trial to assess the effect of combination of ACEI and ARB in patients with diabetes and proteinuria on progression of kidney disease.